The first one to be granted an authorization for the treatment of adult patients with CLL or small lymphocytic lymphoma (SLL) who have received at least two lines of therapy, including a BTK and a BCL-2 inhibitor, was pirtobrutinib. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.